Traws Pharma Files Clinical Trial Application With FDA For Tivoxavir Marboxil, a Single Oral Tablet Administered For Influenza, Full Study Enrollment Expected In January 2026
Benzinga Newsdesk 10 months ago
BiotechNewsHealth CareFDAGeneral
IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpileUpdated clinical
- IND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile
- Updated clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds and faster time to sustained symptom resolution
- Ratutrelvir's safety and efficacy advantage recapitulated in PAXLOVID®-ineligible patients, representing a significant population with few effective treatment options